7776.T
Takeda Pharmaceutical Company Limited develops, manufactures, and sells pharmaceutical products for various therapeutic areas, including oncology, gastroenterology, and rare diseases.
Business. Takeda Pharmaceutical Company Limited develops, manufactures, and sells pharmaceutical products for various therapeutic areas, including oncology, gastroenterology, and rare diseases.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Takeda Pharmaceutical Company Limited develops, manufactures, and sells pharmaceutical products for various therapeutic areas, including oncology, gastroenterology, and rare diseases.
Takeda's capital structure is characterized by a low debt-to-equity ratio of 0.1, indicating a conservative leverage position relative to its equity base. The company maintains a strong liquidity position, with cash and equivalents amounting to ¥1,318,909 million, significantly exceeding its total liabilities of ¥387,459 million. This results in a current ratio of 6.13, suggesting robust short-term liquidity.
Profitability metrics reveal a challenging financial performance, with a negative return on equity of -87.05% and a return on assets of -66.68%. These figures indicate that Takeda is currently generating losses relative to its equity and asset base, which is below the typical performance of the pharmaceutical industry.
Takeda's revenue is concentrated in a few key therapeutic areas, with oncology and gastroenterology being the primary contributors. The company's geographic exposure is primarily in Japan, North America, and Europe, with a significant portion of its revenue derived from these regions. This concentration may expose the company to regional economic and regulatory risks.
The company's growth trajectory is mixed, with a reported revenue of ¥83,678 million in the latest period. However, the operating income and net income are both negative, indicating a decline in profitability. The outlook for the current fiscal year suggests continued financial pressure, with no significant improvement in the near term.
Risk factors for Takeda include the potential for dilution, although the current risk is assessed as low. The company has not issued additional shares recently, and there are no immediate filing-based liquidity or dilution flags. However, the negative operating cash flow of ¥988,976 million and the capital expenditure of ¥26,717 million highlight the need for careful financial management.
Recent events include the company's ongoing efforts to streamline operations and focus on high-potential therapeutic areas. Takeda has also been involved in several strategic partnerships and acquisitions to enhance its product pipeline. These activities are aimed at improving long-term profitability and market position.
- Takeda maintains a strong liquidity position with a current ratio of 6.13 and significant cash reserves.
- The company is currently unprofitable, with a negative return on equity and return on assets.
- Revenue is concentrated in a few therapeutic areas and geographic regions, which may pose concentration risks.
- Takeda's growth trajectory is mixed, with a decline in profitability despite a stable revenue base.
- The company has a low risk of dilution and no immediate liquidity concerns.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 7776.T Market data — financials · 2026-05-27